CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 163 enrolled
Drug / intervention
Stereotactic Body Radiation Therapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00977860
NCT00977860N/ACompleted
CompareCT.gov

Prospective Evaluation Of Hypofractionated Stereotactic Body Radiotherapy For Low And Intermediate Risk Prostate Cancer

Adam Olson·interventional·Posted Sep 16, 2009·Updated May 2, 2024

In Brief

A clinical study evaluating Stereotactic Body Radiation Therapy for Prostate Cancer. Completed, enrolled 163 participants across 1 site.

Detailed Summary

The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to estimate the rate of biochemical Disease-Free Survival, Phoenix and American Society for Therapeutic Radiology and Oncology definitions, at 2 years following hypofractionated stereotactic body radiation therapy for low and intermediate risk prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 16, 2009
Enrollment StartOct 7, 2010
Primary CompletionJul 8, 2022
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 16.8 years ago

Interventions

Stereotactic Body Radiation Therapyradiation

36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period